STZ-diabetic rat heart maintains developed tension amplitude by increasing sarcomere length and crossbridge density.
crossbridges
myocardial contractility
streptozotocin-induced diabetes
Journal
Experimental physiology
ISSN: 1469-445X
Titre abrégé: Exp Physiol
Pays: England
ID NLM: 9002940
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
09
08
2020
accepted:
04
05
2021
pubmed:
13
5
2021
medline:
1
4
2022
entrez:
12
5
2021
Statut:
ppublish
Résumé
What is the central question of this study? In the papillary muscle from type I diabetic rats, does diabetes-associated altered ventricular function result from changes of acto-myosin interactions and are these modifications attributable to a possible sarcomere rearrangement? What is the main finding and its importance? For the first time, we showed that type-I diabetes altered sarcomeric ultrastructure, as seen by transmission electron microscopy, consistent with physiological parameters. The diabetic condition induced slower timing parameters, which is compatible with a diastolic dysfunction. At the sarcomeric level, augmented β-myosin heavy chain content and increased sarcomere length and crossbridges' number preserve myocardial stroke and could concur to maintain the ejection fraction. We investigated whether diabetes-associated altered ventricular function, in a type I diabetes animal model, results from a modification of acto-myosin interactions, through the in vitro recording of left papillary muscle mechanical parameters and examination of sarcomere morphology by transmission electron microscopy (TEM). Experiments were performed on streptozotocin-induced diabetic and age-matched control female Wistar rats. Mechanical isometric and isotonic indexes and timing parameters were determined. Using Huxley's equations, we calculated mechanics, kinetics and energetics of myosin crossbridges. Sarcomere length and A-band length were measured on TEM images. Type I and III collagen and β-myosin heavy chain (MHC) expression were determined by immunoblotting. No variation in resting and developed tension or maximum extent of shortening was evident between groups, but diabetic rats showed lower maximum shortening velocity and prolonged timing parameters. Compared to controls, diabetics also displayed a higher number of crossbridges with lower unitary force. Moreover, no change in type I and III collagen was associated to diabetes, but pathological rats showed a two-fold enhancement of β-MHC content and longer sarcomeres and A-band, detected by ultrastructural morphometry. Overall, these data address whether a preserved systolic function accompanied by an altered diastolic phase results from a recruitment of super-relaxed myosin heads or the phosphorylation of the regulatory light chain site in myosin. Although the early signs of diabetic cardiomyopathy were well expressed, the striking finding of our study was that, in diabetics, sarcomere modification may be a possible compensatory mechanism that preserves systolic function.
Identifiants
pubmed: 33977604
doi: 10.1113/EP089000
pmc: PMC8362044
doi:
Substances chimiques
Streptozocin
5W494URQ81
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1572-1586Informations de copyright
© 2021 The Authors. Experimental Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
Références
Am J Physiol. 1981 Sep;241(3):H348-53
pubmed: 7282943
Eur J Heart Fail. 2011 Jun;13(6):664-9
pubmed: 21415098
Arch Histol Cytol. 2010;73(1):37-44
pubmed: 21471665
Biochemistry. 2004 Nov 30;43(47):15058-65
pubmed: 15554713
Cardiovasc Toxicol. 2001;1(1):35-42
pubmed: 12213995
Diabetes Res Clin Pract. 1991 Mar;11(3):177-88
pubmed: 2036940
Exp Physiol. 2021 Jul;106(7):1572-1586
pubmed: 33977604
World J Cardiol. 2020 Jan 26;12(1):7-25
pubmed: 31984124
Diabetes Res Clin Pract. 2014 Feb;103(2):137-49
pubmed: 24630390
Am J Physiol Heart Circ Physiol. 2000 Jul;279(1):H238-44
pubmed: 10899062
Proc Soc Exp Biol Med. 1994 Apr;205(4):294-305
pubmed: 8171052
Diabetes. 2008 Aug;57(8):2158-66
pubmed: 18492789
Proc Natl Acad Sci U S A. 2018 Aug 28;115(35):E8143-E8152
pubmed: 30104387
Proc R Soc Lond B Biol Sci. 1964 Jan 14;159:319-24
pubmed: 14114167
Diabetes. 1980 Jul;29(7):579-82
pubmed: 6445843
Am J Respir Crit Care Med. 1995 Jan;151(1):123-8
pubmed: 7812541
Diabetes. 2002 Apr;51(4):1166-71
pubmed: 11916940
J Am Coll Cardiol. 2004 Dec 21;44(12):2390-7
pubmed: 15607403
Oral Dis. 2014 Nov;20(8):796-802
pubmed: 24245711
Metabolism. 1997 Jan;46(1):71-5
pubmed: 9005973
Biol Open. 2021 Feb 15;10(2):
pubmed: 33589442
Circ J. 2006 Mar;70(3):327-34
pubmed: 16501301
Circ Res. 1980 Dec;47(6):922-33
pubmed: 7438339
J Anat. 2013 Nov;223(5):519-24
pubmed: 23998562
World J Diabetes. 2015 Jul 10;6(7):943-60
pubmed: 26185602
Acta Diabetol. 2000;37(3):119-24
pubmed: 11277311
Am J Physiol. 1987 Feb;252(2 Pt 2):H275-82
pubmed: 2949630
Circulation. 2015 Apr 7;131(14):1247-59
pubmed: 25637629
J Am Coll Cardiol. 2006 Feb 21;47(4):693-700
pubmed: 16487830
Eur Respir J. 2003 Aug;22(2):227-34
pubmed: 12952252
J Mol Cell Cardiol. 2010 May;48(5):910-6
pubmed: 20184888
Monogr Physiol Soc. 1985;41:1-357
pubmed: 3843415
J Physiol. 1971 Oct;218 Suppl:59P-60P
pubmed: 5130636
Am J Cardiol. 2019 Feb 15;123(4):611-617
pubmed: 30612727
Exp Physiol. 2015 Jul 1;100(7):755-8
pubmed: 26076765
Circulation. 2017 Feb 21;135(8):736-740
pubmed: 28052978
J Physiol. 2000 Aug 15;527 Pt 1:85-94
pubmed: 10944172
Physiol Rev. 2017 Jan;97(1):1-37
pubmed: 27807199
J Physiol. 1999 Sep 15;519 Pt 3:669-78
pubmed: 10457082
Nature. 1971 Oct 22;233(5321):533-8
pubmed: 4939977
Am J Physiol Heart Circ Physiol. 2011 May;300(5):H1661-8
pubmed: 21335468
Cardiovasc Diabetol. 2014 Apr 09;13:75
pubmed: 24712865
Basic Res Cardiol. 2005 May;100(3):231-9
pubmed: 15645163
Am J Physiol Cell Physiol. 2019 Aug 1;317(2):C226-C234
pubmed: 31091146
Circulation. 2008 Jan 1;117(1):43-51
pubmed: 18071071
Biofactors. 2010 May-Jun;36(3):229-39
pubmed: 20533397
J Mol Cell Cardiol. 2015 Aug;85:199-206
pubmed: 26057075
Cardiovasc Res. 1997 Apr;34(1):34-40
pubmed: 9217870
Circ Res. 2009 Jan 2;104(1):95-103
pubmed: 19023131
Cardiovasc Drugs Ther. 1994 Feb;8(1):65-73
pubmed: 8086330
Cardiovasc Res. 1997 Apr;34(1):230-40
pubmed: 9217895
Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):H2109-19
pubmed: 19820199
Cardiovasc Res. 1998 Nov;40(2):239-47
pubmed: 9893715
Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):H2096-108
pubmed: 19801494
Cardiovasc Diabetol. 2014 Apr 15;13:79
pubmed: 24731754
Biofactors. 2005;25(1-4):127-35
pubmed: 16873937
J Clin Invest. 1990 Aug;86(2):481-8
pubmed: 2200804
Am J Physiol Regul Integr Comp Physiol. 2007 Nov;293(5):R1787-97
pubmed: 17761517
Soc Gen Physiol Ser. 1982;37:173-88
pubmed: 6216597
Heart Fail Rev. 2012 May;17(3):325-44
pubmed: 21626163
FASEB J. 1998 Aug;12(11):981-9
pubmed: 9707170
Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):8177-8186
pubmed: 32220962
J Endocrinol. 2004 Jan;180(1):175-82
pubmed: 14709156
Biophys J. 1980 Feb;29(2):195-227
pubmed: 6455168
Acta Physiol Scand. 1999 Jun;166(2):137-44
pubmed: 10383493
Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H247-56
pubmed: 19395549
Physiol Rev. 2019 Jan 1;99(1):381-426
pubmed: 30379622
Biochim Biophys Acta. 1996 Feb 15;1273(2):73-6
pubmed: 8611591
Ther Adv Chronic Dis. 2015 Nov;6(6):347-74
pubmed: 26568811
Arch Intern Med. 1998 Mar 23;158(6):617-21
pubmed: 9521226